Incentive to use? |
In the decision “Glasfasern”, the German Bundesgerichtshof (BGH) had to rule in the novelty and inventivess
of a “use” claim. The patent had been granted on the idea of using a particular
kind of glass fibre material as glass fibre “not having cancerogenic potential”.
The glass
fibre as such was (besides of some very minor differences not giving rise to an
inventive step) known from at least one document in the prior art. In the same
document, it was noted that the glass fibre would presumably have cancerogenic
properties (in particular when minute fragments accumulate in the lung of workers using the material for building insulation) and that two independent institutes had been entrusted to carry out
an investigation on this issue.
According
to the established case-law in Germany, the anticipation of “use” claims does
not require evidence that the “use” has actually taken place. Rather, it is
sufficient if the product or substance has been evidently prepared (“sinnfällig
hergereichtet”) for such a use, e.g. by using a design adapted to that use or
by supplementing the product or substance with a user manual or package leaflet
disclosing the possible use.
In the case
at issue, the presumption of cancerogenic properties was not considered sufficient
to establish a lack of novelty.
Further,
this presumption together with the information that studies in this regard had
already been commissioned did not constitute an incentive for the skilled
person to carry out these (expensive and complex) studies by himself.
An
interesting point in this decision is that the “use” was not limited to a
particular technical application of the glass fibre such as building insulation but rather covered all
applications where cancerogenic potential was undesired (difficult to imaging where this is not the case). The discovery of a yet unknown
property (here: lack of cancerogenic potential) of a known substance gives the discoverer
the exclusive right to use the substance in applications where this property is
relevant.
No comments:
Post a Comment